Hung-Tsung Wu1,2, Horng-Yih Ou3, Hao-Chang Hung3,4, Yu-Chu Su4, Feng-Hwa Lu2, Jin-Shang Wu2, Yi-Ching Yang2, Chao-Liang Wu5,6, Chih-Jen Chang7,8. 1. Research Center of Clinical Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. 2. Department of Family Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng-Li Road, Tainan, 70403, Taiwan. 3. Division of Endocrinology and Metabolism, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. 4. Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. 5. Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. wumolbio@mail.ncku.edu.tw. 6. Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, 1 University Road, Tainan, 70101, Taiwan. wumolbio@mail.ncku.edu.tw. 7. Department of Family Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng-Li Road, Tainan, 70403, Taiwan. changcj.ncku@gmail.com. 8. Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. changcj.ncku@gmail.com.
Abstract
AIMS/HYPOTHESIS: Type 2 diabetes is highly correlated with nonalcoholic fatty liver disease (NAFLD). Hepatocyte-derived fibrinogen-related protein 1 (HFREP1) is a hepatokine that mediates NAFLD development; however, the role of HFREP1 in the development of insulin resistance and diabetes remains obscure. METHODS: A total of 193 age- and sex-matched participants with normal glucose tolerance, impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and newly diagnosed diabetes (NDD) were recruited for a cross-sectional study. Plasma HFREP1 levels were measured and multivariate linear regression analysis was used to evaluate the relationship between HFREP1, IFG, IGT and NDD. The causal relationship between HFREP1 and insulin resistance was then investigated in animal and cell models. Glucose and insulin tolerance tests, and euglycaemic-hyperinsulinaemic clamp, were used to evaluate insulin sensitivity in animals with Hfrep1 overexpression or knockdown in liver by lentiviral vectors. HepG2 cells were used to clarify the possible mechanism of HFREP1-induced insulin resistance. RESULTS: Plasma HFREP1 concentrations were significantly increased in participants with IFG, IGT and NDD. HFREP1 concentrations were independently associated with fasting plasma glucose levels, insulin resistance, IFG, IGT and NDD. Injection of recombinant HFREP1 or Hfrep1 overexpression induced insulin resistance in mice, and HFREP1 disrupted insulin signalling to induce insulin resistance through an extracellular signal-regulated kinase (ERK)1/2-dependent pathway. Moreover, hepatic knockdown of HFREP1 improved insulin resistance in both mice fed a high-fat diet and ob/ob mice. CONCLUSIONS/ INTERPRETATION: These findings highlight the crucial role of HFREP1 in insulin resistance and diabetes, and provide a potential strategy and biomarker for developing therapeutic approaches to combat these diseases.
AIMS/HYPOTHESIS: Type 2 diabetes is highly correlated with nonalcoholic fatty liver disease (NAFLD). Hepatocyte-derived fibrinogen-related protein 1 (HFREP1) is a hepatokine that mediates NAFLD development; however, the role of HFREP1 in the development of insulin resistance and diabetes remains obscure. METHODS: A total of 193 age- and sex-matched participants with normal glucose tolerance, impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and newly diagnosed diabetes (NDD) were recruited for a cross-sectional study. Plasma HFREP1 levels were measured and multivariate linear regression analysis was used to evaluate the relationship between HFREP1, IFG, IGT and NDD. The causal relationship between HFREP1 and insulin resistance was then investigated in animal and cell models. Glucose and insulin tolerance tests, and euglycaemic-hyperinsulinaemic clamp, were used to evaluate insulin sensitivity in animals with Hfrep1 overexpression or knockdown in liver by lentiviral vectors. HepG2 cells were used to clarify the possible mechanism of HFREP1-induced insulin resistance. RESULTS: Plasma HFREP1 concentrations were significantly increased in participants with IFG, IGT and NDD. HFREP1 concentrations were independently associated with fasting plasma glucose levels, insulin resistance, IFG, IGT and NDD. Injection of recombinant HFREP1 or Hfrep1 overexpression induced insulin resistance in mice, and HFREP1 disrupted insulin signalling to induce insulin resistance through an extracellular signal-regulated kinase (ERK)1/2-dependent pathway. Moreover, hepatic knockdown of HFREP1 improved insulin resistance in both mice fed a high-fat diet and ob/ob mice. CONCLUSIONS/ INTERPRETATION: These findings highlight the crucial role of HFREP1 in insulin resistance and diabetes, and provide a potential strategy and biomarker for developing therapeutic approaches to combat these diseases.
Authors: Stefan Kiechl; Jürgen Wittmann; Andrea Giaccari; Michael Knoflach; Peter Willeit; Aline Bozec; Alexander R Moschen; Giovanna Muscogiuri; Gian Pio Sorice; Trayana Kireva; Monika Summerer; Stefan Wirtz; Julia Luther; Dirk Mielenz; Ulrike Billmeier; Georg Egger; Agnes Mayr; Friedrich Oberhollenzer; Florian Kronenberg; Michael Orthofer; Josef M Penninger; James B Meigs; Enzo Bonora; Herbert Tilg; Johann Willeit; Georg Schett Journal: Nat Med Date: 2013-02-10 Impact factor: 53.440
Authors: Julio E Ayala; Deanna P Bracy; Carlo Malabanan; Freyja D James; Tasneem Ansari; Patrick T Fueger; Owen P McGuinness; David H Wasserman Journal: J Vis Exp Date: 2011-11-16 Impact factor: 1.355
Authors: Y Zhang; D Dilimulati; D Chen; M Cai; H You; H Sun; X Gao; X Shao; M Zhang; S Qu Journal: J Endocrinol Invest Date: 2022-07-05 Impact factor: 5.467